everything but topic 6

• Digoxin (Lanoxin)

  • Classification: Cardiac glycoside; positive inotrope and negative chronotrope/dromotrope.

  • Mechanism of Action: Inhibits myocardial sarcolemmal sodium-potassium adenosine triphosphatase ($Na^+\text{--}K^+$ ATPase), increasing intracellular sodium and activating the sodium-calcium exchanger; the resulting influx of free intracellular calcium enhances myocardial contractility ($\uparrow$ inotropy) and improves cardiac output ($CO$); concurrently increases vagal parasympathetic tone, slowing sinoatrial firing ($\downarrow$ chronotropy) and prolonging atrioventricular node refractory conduction ($\downarrow$ dromotropy).

  • Indications & Uses: Advanced heart failure with reduced ejection fraction (HFrEF); ventricular rate control in atrial fibrillation and atrial flutter.

  • Therapeutic Target Level: In heart failure, target serum concentration is narrow: $0.5\text{ to }1.0\,\text{ng/mL}$.

  • Adverse Reactions & Side Effects:

    • Common Early Toxicity Signs: Anorexia, nausea, vomiting, diarrhea, generalized malaise, dizziness, headache, mental confusion, and cognitive delirium (predominant in older adults).

    • Visual Hallmarks: Photophobia, blurred vision, diplopia, and pathognomonic green-yellow halos around light sources.

    • Severe & Life-Threatening: Sinus bradycardia, high-grade AV block, paroxysmal atrial tachycardia with block, ventricular bigeminy, ventricular tachycardia, and lethal ventricular fibrillation; thrombocytopenia.

  • Contraindications, Cautions & Nursing Checks:

    • Contraindications: Ventricular fibrillation.

    • Cautions: Recent acute myocardial infarction, second- or third-degree AV block, hypokalemia ($\downarrow K^+$), hypomagnesemia ($\downarrow Mg^{2+}$), hypercalcemia ($\uparrow Ca^{2+}$), severe renal insufficiency, advanced age, hypothyroidism (requires dose reduction due to slowed elimination), and hyperthyroidism (requires dose increase).

    • Pre-Administration Assessment: Auscultate apical pulse for $1\text{ full minute}$; strictly HOLD medication if $HR < 60\,\text{beats/min}$.

    • Laboratory Monitoring: Serial monitoring of serum digoxin level ($0.5\text{ to }1.0\,\text{ng/mL}$) and serum potassium ($3.5\text{ to }5.0\,\text{mEq/L}$). Hypokalemia sensitizes the myocardium to digoxin, precipitating life-threatening toxicity.

    • Interactions: Potassium-wasting diuretics (furosemide, hydrochlorothiazide) and systemic corticosteroids drop potassium and trigger toxicity; diltiazem, verapamil, and quinidine increase digoxin concentrations; antacids, cholestyramine, and psyllium bind digoxin and reduce GI absorption.

  • Antidote: Digoxin immune Fab (Digibind / DigiFab) fragments bind and neutralize circulating free digoxin.

  • Patient Education:

    • Self-monitor pulse daily prior to dosing; withhold and contact clinic if heart rate drops below $60\,\text{beats/min}$.

    • Promptly report gastrointestinal distress (anorexia, nausea), palpitations, visual disruptions, or yellow-green halos.

    • Maintain dietary potassium intake through potassium-rich foods (bananas, potatoes, oranges) unless concurrently prescribed potassium-sparing agents.

  • Memory Hooks: "Sixty, Dig, hold"; therapeutic level = "half to one"; "low K = toxic Dig"; Digibind makes toxicity "Fab-ulous."

• Nitroglycerin (Nitrostat / Nitro-Bid / Nitro-Dur)

  • Classification: Nitrate; antianginal vasodilator.

  • Mechanism of Action: Converted to nitric oxide within vascular smooth muscle, stimulating cyclic guanosine monophosphate (cGMP) synthesis; relaxes systemic vascular smooth muscle, causing profound peripheral venous dilation (reducing venous return, preload, and ventricular wall tension) and moderate arterial dilation (reducing afterload); dilates epicardial coronary vessels to redistribute blood flow to ischemic myocardium.

  • Indications & Uses: Treatment and prophylaxis of angina pectoris; acute myocardial infarction (MI); acute pulmonary edema; hypertensive emergencies; refractory congestive heart failure.

  • Expected Therapeutic Effects: Rapid alleviation of anginal chest pain; reduction in myocardial oxygen consumption.

  • Adverse Reactions & Side Effects:

    • Common Side Effects: Severe throbbing vascular headache (most common adverse event due to cerebral vasodilation), cutaneous flushing, dizziness, syncope, diaphoresis, nausea, dry mouth, weakness, local application rash, and tolerance.

    • Severe & Life-Threatening: Profound orthostatic hypotension, reflex tachycardia, paradoxical bradycardia, localized facial/lip angioedema, and complete circulatory collapse.

  • Contraindications, Cautions & Nursing Checks:

    • Contraindications: Co-administration with phosphodiesterase-5 (PDE-5) inhibitors (sildenafil, tadalafil, vardenafil) is strictly prohibited due to irreversible, fatal refractory hypotension; elevated intracranial pressure (ICP); severe anemia; hypertrophic cardiomyopathy; cardiac tamponade; hypovolemic or cardiogenic shock.

    • Hold Parameters: Measure blood pressure immediately prior to and after administration; strictly HOLD if systolic blood pressure is $SBP < 90\,\text{mmHg}$ or drops $\ge 30\,\text{mmHg}$ below baseline.

    • Administration Checks: Client must sit or recline during initial doses to prevent syncopal falls.

  • Patient Education & Nitroglycerin Protocols:

    • Sublingual (SL) Tablet / Spray Protocol for Acute Angina: At the onset of chest discomfort, rest immediately in a seated position. Place $1\,\text{tablet}$ under tongue (or spray $1\,\text{dose}$ onto oral mucosa); do not swallow or chew. If discomfort persists after $5\,\text{minutes}$, immediately call emergency medical services (911), then take a second dose. A maximum of $3\,\text{doses}$ may be taken over $15\,\text{minutes}$ ($1\,\text{tablet every } 5\,\text{minutes} \times 3$).

    • Storage: Store tablets in original, airtight, light-resistant dark amber glass bottle; keep away from heat, moisture, and direct light; discard after expiration because potency drops rapidly.

    • Transdermal Patches: Apply daily to clean, dry, hairless skin; rotate application sites; maintain an essential $10\text{ to }12\,\text{hour}$ nitrate-free interval (typically overnight) to prevent hemodynamic vascular tolerance.

    • Avoid all alcoholic beverages and verify absence of PDE-5 medications.

  • Memory Hooks: "SBP under 90, no nitro"; "Nitro + Viagra = Nope"; "5-5-3: 5 minutes apart, 3 doses max, call 911 early."

• Atenolol (Tenormin)

  • Classification: Selective beta1-adrenergic receptor antagonist (cardioselective beta blocker).

  • Mechanism of Action: Competitively and selectively antagonizes cardiac beta1-adrenergic receptors, reducing resting and exercise heart rates ($\downarrow$ chronotropy), myocardial contractile force ($\downarrow$ inotropy), and cardiac output; suppresses sympathetic outflow from the CNS and inhibits renal juxtaglomerular renin release to suppress the renin-angiotensin-aldosterone system (RAAS).

  • Indications & Uses: Long-term management of hypertension; chronic stable angina pectoris; post-myocardial infarction secondary prophylaxis to reduce mortality.

  • Expected Therapeutic Effects: Sustained reduction in systemic blood pressure, decrease in anginal frequency, and prevention of ischemic reinfarction.

  • Adverse Reactions & Side Effects:

    • Common Side Effects: Fatigue, generalized weakness, depression, cold extremities (peripheral vasoconstriction), nausea, diarrhea, dizziness, and erectile dysfunction.

    • Masking Effect: Masks autonomic signs of hypoglycemia in diabetic clients (tachycardia, palpitations, and tremors are suppressed; diaphoresis remains intact as the primary warning sign).

    • Severe & Life-Threatening: Marked bradycardia, advanced AV heart block, acute decompensated heart failure, pulmonary edema, severe bronchospasm (loss of cardioselectivity at elevated doses), thrombocytopenia, and rebound hypertensive crisis / lethal myocardial infarction following abrupt discontinuation.

  • Contraindications, Cautions & Nursing Checks:

    • Contraindications: Sinus bradycardia ($HR < 50\text{ to }60\,\text{beats/min}$), second- or third-degree heart block, cardiogenic shock, overt cardiac failure, acute bronchospastic disease (asthma, severe COPD), and pregnancy/lactation (contraindicated due to fetal growth restriction and neonatal toxicity).

    • Cautions & Pharmacokinetics: Renally excreted; adjust dose in renal impairment. Caution in diabetes mellitus and peripheral vascular disease.

    • Hold Parameters: Measure BP and apical pulse prior to dosing; hold if apical $HR < 60\,\text{beats/min}$ or systolic $BP < 90\,\text{mmHg}$ (or per institutional orders).

    • Interactions: NSAIDs blunt antihypertensive efficacy; anticholinergics increase gastrointestinal absorption; concurrent insulin or oral sulfonylureas precipitate hypoglycemia and mask symptoms.

  • Antidote: Atropine IV for symptomatic bradycardia; IV glucagon for severe overdose refractory to atropine.

  • Patient Education:

    • Never abruptly discontinue beta-blocker therapy; sudden cessation triggers rebound sympathetic surge, severe angina, and rebound hypertension.

    • Maintain a weekly resting blood pressure and heart rate log.

    • Diabetic individuals must recognize diaphoresis (sweating) as the primary indicator of hypoglycemia.

    • Rise slowly from seated or lying positions to prevent orthostatic dizziness.

  • Memory Hooks: "-olol = beta blocker"; "A-TEN-olol = kidney-cleared"; "Sweat is the clue" for hypoglycemia.

• Diltiazem (Cardizem)

  • Classification: Non-dihydropyridine calcium channel blocker (benzothiazepine class).

  • Mechanism of Action: Inhibits the transmembrane influx of extracellular calcium ions through voltage-gated L-type calcium channels into vascular smooth muscle and myocardial cells; causes relaxation of coronary arterial beds (relieving vasospasm), promotes systemic peripheral arterial vasodilation (lowering afterload and BP), and depresses SA node automaticity and AV node conduction velocity.

  • Indications & Uses: Chronic stable angina, vasospastic (Prinzmetal's) angina, and essential systemic hypertension. Notably recognized in clinical guidelines as the most effective single antihypertensive and antianginal drug class in African-American individuals.

  • Expected Therapeutic Effects: Controlled reduction in arterial blood pressure, elimination of coronary vasospasm, reduction in anginal frequency, and reduction in myocardial oxygen consumption.

  • Adverse Reactions & Side Effects:

    • Common Side Effects: Peripheral lower-extremity edema, vascular headache, dizziness, fatigue, flushing, nausea, and severe constipation.

    • Severe & Life-Threatening: Marked bradycardia, high-grade or complete atrioventricular (AV) heart block, worsening congestive heart failure, severe hypotension, and toxic dysrhythmias when combined with other nodal-blocking agents.

  • Contraindications, Cautions & Nursing Checks:

    • Contraindications: Sick sinus syndrome, second- or third-degree AV block (without a functioning ventricular pacemaker), severe hypotension ($SBP < 90\,\text{mmHg}$), acute MI with pulmonary congestion, and cardiogenic shock.

    • High-Risk Combinations: Concurrent administration with digoxin or beta-adrenergic blockers forms the lethal "Heart-Block Trio" (profound additive bradycardia, AV block, and depression of myocardial contractility); diltiazem raises serum digoxin concentrations.

    • Checks: Continuous baseline and serial assessment of heart rate, seated blood pressure, and 12-lead ECG.

  • Antidote: Intravenous Calcium Chloride ($CaCl_2$) or Calcium Gluconate reverses severe CCB-induced hypotension and AV conduction block; IV Atropine treats profound sinus bradycardia.

  • Patient Education:

    • Review all complementary herbs: avoid St. John's wort and ginseng (lower therapeutic drug levels); avoid excessive garlic and hawthorn (potentiate severe hypotension).

    • Adhere to universal antihypertensive principles: self-monitor BP and heart rate weekly, maintain lifestyle adjustments, and avoid abrupt drug discontinuation.

    • Report sudden weight gain, dependent peripheral swelling, extreme fatigue, or dizziness.

  • Memory Hooks: "DILTiazem DILates"; "Calcium for Calcium blocker" ($CaCl_2$ antidote); "Dilt + Dig + Beta Blocker = Heart-Block Trio."

• Hydrochlorothiazide (HCTZ / Microzide)

  • Classification: Thiazide diuretic; antihypertensive.

  • Mechanism of Action: Inhibits the active sodium-chloride ($Na^+/Cl^-$) symporter in the luminal membrane of the early distal convoluted tubule; increases renal excretion of sodium, chloride, potassium, and free water; reduces circulating plasma volume and cardiac preload; enhances distal tubular calcium reabsorption ($\uparrow Ca^{2+}$); chronic administration reduces total peripheral vascular resistance.

  • Indications & Uses: First-line baseline pharmacotherapy for uncomplicated essential hypertension; adjunctive management of mild-to-moderate peripheral edema secondary to heart failure, hepatic cirrhosis, and renal dysfunction; secondary prevention of recurrent calcium nephrolithiasis.

  • Expected Therapeutic Effects: Progressive reduction in baseline blood pressure over $2\text{ to }4\,\text{weeks}$; resolution of dependent peripheral edema.

  • Adverse Reactions & Side Effects:

    • Metabolic Disturbance ("Hyper-G-L-U-C"): Hyperglycemia, hyperlipidemia, hyperuricemia (triggers acute gout attacks), and hypercalcemia.

    • Electrolyte Depletion: Hypokalemia ($\downarrow K^+$; causes muscle weakness and lethal dysrhythmias), hyponatremia ($\downarrow Na^+$; triggers neurological confusion and seizures), hypochloremia, and hypomagnesemia ($\downarrow Mg^{2+}$).

    • Other Effects: Dizziness, orthostatic hypotension, photosensitivity, nausea, and dehydration.

    • Severe & Life-Threatening: Profound hypokalemia ($K^+ < 3.0\,\text{mEq/L}$) with ventricular arrhythmias, severe acute renal failure (AKI), bone marrow depression (aplastic anemia, thrombocytopenia), and Stevens-Johnson syndrome.

  • Contraindications, Cautions & Nursing Checks:

    • Contraindications: Anuria, documented hypersensitivity to sulfonamide-derived medications, and severe renal failure (ineffective when GFR drops below $30\,\text{mL/min}$).

    • Cautions: Gout, diabetes mellitus, systemic lupus erythematosus (SLE; photosensitivity flares), hepatic impairment, and older adults.

    • Hold Parameters: Assess sitting and standing blood pressure, daily weight, fluid balance (I&O), and basic metabolic panel (BMP); HOLD if $SBP < 90\,\text{mmHg}$ or client is acutely symptomatic.

    • Interactions: Induces hypokalemia, precipitating fatal digoxin toxicity; reduces renal lithium clearance, causing lithium toxicity; NSAIDs blunt diuretic and antihypertensive efficacy; licorice and aloe accelerate potassium wasting.

  • Patient Education:

    • Take daily in the morning to prevent nocturia and sleep interruption.

    • Use sunscreens (SPF) and protective attire due to photosensitivity.

    • Rise slowly from lying/sitting to prevent orthostatic falls.

    • Promptly report symptoms of hypokalemia (muscle cramps, weakness, palpitations) or acute gout (severe great-toe pain).

  • Memory Hooks: HCTZ = "Hyper-G-L-U-C" (hyperGlycemia, hyperLipidemia, hyperUricemia, hyperCalcemia); saves calcium while losing sodium, potassium, and magnesium.

• Furosemide (Lasix)

  • Classification: High-ceiling loop diuretic (sulfonamide derivative).

  • Mechanism of Action: Selectively binds to and inhibits the luminal $Na^+\text{--}K^+\text{--}2Cl^-$ co-transporter in the thick ascending limb of the loop of Henle; completely blocks active reabsorption of sodium and chloride, abolishing the hypertonic medullary gradient; delivers massive solute loads to the collecting duct, inducing massive urinary excretion of sodium, chloride, potassium, hydrogen, magnesium, and calcium ($\downarrow Ca^{2+}$); promotes renal synthesis of prostaglandins, enhancing renal blood flow.

  • Indications & Uses: Rapid diuresis for acute pulmonary edema, decompensated congestive heart failure, hepatic ascites, nephrotic syndrome, and chronic kidney disease volume overload (retains diuretic efficacy even in severe low GFR states); hypertensive emergencies.

  • Expected Therapeutic Effects: Rapid, high-volume diuresis within $5\,\text{minutes}$ (IV) or $1\,\text{hour}$ (oral); rapid reduction in intravascular volume, pulmonary congestion, peripheral edema, body weight, and dyspnea.

  • Adverse Reactions & Side Effects:

    • Fluid and Electrolytes: Profound dehydration, marked hypokalemia, severe hyponatremia, hypomagnesemia, hypocalcemia, hypochloremic metabolic alkalosis, and hyperuricemia.

    • Common Side Effects: Dizziness, severe orthostatic hypotension, headache, and transient hyperglycemia.

    • Severe & Life-Threatening: Irreversible or reversible ototoxicity and severe tinnitus (associated with rapid IV bolus administration or concurrent ototoxic agents), acute renal failure, thrombocytopenia, agranulocytosis, and Stevens-Johnson syndrome.

  • Contraindications, Cautions & Nursing Checks:

    • Contraindications: Anuria, hepatic coma, severe uncorrected electrolyte depletion, and severe hypovolemia.

    • Cautions: Severe sulfonamide allergy, diabetes mellitus, gout, and SLE.

    • Critical Nursing Assessments: Closely track urine output at least every $8\,\text{hours}$ (hourly in acute ICU settings); notify provider immediately if urine output is $UO < 30\,\text{mL/h}$; record daily morning weight on the same scale; report acute body weight changes $\ge 1\,\text{kg/24 h}$ (representing approximately $1\,\text{L}$ of fluid).

    • IV Administration Rule: Infuse slowly at an IV push rate not exceeding $20\text{ to }40\,\text{mg/min}$ to prevent transient or permanent ototoxicity.

    • Interactions: Concurrent aminoglycosides (gentamicin) or cisplatin markedly increase ototoxicity risk; potentiates digoxin toxicity via hypokalemia; NSAIDs attenuate diuretic efficacy; licorice severely accelerates potassium loss.

  • Patient Education:

    • Take in the morning; if prescribed twice daily, take the second dose in mid-afternoon to prevent nocturnal urination.

    • Report sudden auditory changes, hearing loss, or ringing in the ears (tinnitus) immediately.

    • Report severe muscle cramps, irregular heartbeats, or severe dizziness upon standing.

    • Consume potassium-rich foods as directed; avoid natural black licorice.

  • Memory Hooks: "FURO = FURious pee"; "Loops lose it all" (loses $K, Na, Mg, Ca$); "Loop, Listen: ototoxic if pushed fast."

• Spironolactone (Aldactone)

  • Classification: Potassium-sparing diuretic; synthetic selective aldosterone antagonist.

  • Mechanism of Action: Competitively antagonizes intracellular mineralocorticoid aldosterone receptors in the late distal convoluted tubule and cortical collecting duct; inhibits aldosterone-induced protein synthesis, preventing sodium-potassium exchange mechanisms; increases urinary excretion of sodium, chloride, and water while completely preserving potassium and hydrogen ions.

  • Indications & Uses: Management of primary hyperaldosteronism; adjunctive therapy for refractory edema in congestive heart failure and hepatic cirrhosis (ascites); essential hypertension; treatment and prevention of diuretic-induced hypokalemia.

  • Expected Therapeutic Effects: Mild sustained diuresis and reduction in arterial blood pressure while maintaining serum potassium levels within normal ranges ($3.5\text{ to }5.0\,\text{mEq/L}$) and reducing cardiac remodeling in heart failure.

  • Adverse Reactions & Side Effects:

    • Endocrine Side Effects: Binds non-target steroid receptors, causing gynecomastia in males, breast tenderness, menstrual irregularities, postmenopausal bleeding, and diminished libido.

    • Common Side Effects: Dizziness, headache, nausea, vomiting, abdominal cramping, and orthostatic hypotension.

    • Severe & Life-Threatening: Severe life-threatening hyperkalemia ($K^+ \ge 5.5\,\text{mEq/L}$; manifests with muscle paresthesias, flaccid paralysis, cardiac conduction blocks, tall peaked T waves, widening QRS complexes, bradycardia, and asystole), acute renal failure, and blood dyscrasias.

  • Contraindications, Cautions & Nursing Checks:

    • Contraindications: Baseline hyperkalemia ($K^+ \ge 5.0\,\text{mEq/L}$), anuria, acute renal failure, and significant renal impairment ($CrCl < 30\,\text{mL/min}$).

    • Hold Parameters: Routinely check serum electrolytes (BMP) and renal function; strictly HOLD medication if serum potassium is $K^+ \ge 5.5\,\text{mEq/L}$ or serum creatinine is actively rising.

    • High-Risk Interactions: Co-administration with potassium supplements (potassium chloride), ACE inhibitors (lisinopril), angiotensin receptor blockers (valsartan), or potassium-containing salt substitutes precipitates lethal hyperkalemia.

  • Patient Education:

    • Strictly avoid potassium supplements, salt substitutes formulated with potassium chloride, and excessive dietary potassium.

    • Recognize symptoms of hyperkalemia: muscle weakness, tingling sensation in extremities, nausea, chest pain, and irregular pulse.

    • Take in the morning with food to optimize absorption and limit nocturia.

  • Memory Hooks: "Spiro Spares" potassium; "Gyno-spiro" = gynecomastia; "S-S = Spironolactone Saves K."

• Metoprolol (Lopressor / Toprol-XL)

  • Classification: Cardioselective beta1-adrenergic receptor blocker.

  • Mechanism of Action: Preferentially antagonizes myocardial beta1-adrenergic receptors with minimal initial affinity for bronchial beta2 receptors at physiological doses; diminishes SA node automaticity, slows AV conduction velocity, and reduces myocardial inotropic contractility; suppresses renal renin release, lowering overall circulating angiotensin II and aldosterone levels.

  • Indications & Uses: Management of essential hypertension; chronic stable angina pectoris; post-myocardial infarction secondary prophylaxis; supraventricular tachycardia (SVT) and atrial fibrillation rate control; chronic stable heart failure with reduced ejection fraction (Toprol-XL / metoprolol succinate formulation only).

  • Formulation Warning: Metoprolol tartrate (Lopressor) is immediate-release for hypertension/angina. Metoprolol succinate (Toprol-XL) is extended-release, indicated for heart failure; never crush, chew, or split extended-release tablets.

  • Adverse Reactions & Side Effects:

    • Common Side Effects: Dizziness, fatigue, depression, insomnia, nightmares, dry mouth, nausea, diarrhea, cold extremities, and erectile dysfunction.

    • Severe & Life-Threatening: Profound sinus bradycardia, second- and third-degree AV block, complete heart block, acute decompensated heart failure, cardiogenic shock, bronchospasm (in susceptible asthma/COPD patients at elevated doses), severe hypoglycemia, and rebound angina, severe hypertension, or fatal MI upon abrupt discontinuation.

  • Contraindications, Cautions & Nursing Checks:

    • Contraindications: Second- or third-degree AV block, severe sinus bradycardia, cardiogenic shock, and uncompensated decompensated cardiac failure.

    • Cautions: Asthma, COPD, peripheral vascular disease, depression, and diabetes mellitus.

    • Pre-Administration Parameters: Obtain apical heart rate and blood pressure immediately before administration; withhold and consult provider if apical pulse is $HR < 60\,\text{beats/min}$ or systolic pressure is $SBP < 90\,\text{mmHg}$.

    • Signs of Worsening Heart Failure: Routinely monitor for dependent edema, sudden weight gain, crackles on lung auscultation, and worsening dyspnea.

  • Patient Education:

    • Never crush, chew, or dissolve Toprol-XL (metoprolol succinate) tablets.

    • Never stop taking metoprolol abruptly due to life-threatening rebound effects.

    • Diabetic patients must monitor blood glucose frequently, recognizing that tachycardia is masked, while sweating persists.

    • Report sudden weight gain ($\ge 1\,\text{kg/24 h}$), progressive shortness of breath, or cold swollen feet.

  • Memory Hooks: "Mighty Slow Pulse" (check HR first); "Succinate/XL = Heart Failure, never crush."

• Prazosin (Minipress)

  • Classification: Selective peripherally acting alpha1-adrenergic receptor antagonist.

  • Mechanism of Action: Selectively and competitively inhibits postsynaptic alpha1-adrenergic receptors on vascular smooth muscle; prevents sympathetic norepinephrine-mediated vasoconstriction, producing dilation of systemic arterioles and veins; decreases peripheral vascular resistance and venous return; concurrently relaxes smooth muscle of the prostatic capsule and bladder neck, reducing urinary outflow resistance.

  • Indications & Uses: Treatment of mild-to-moderate systemic hypertension; symptomatic management of benign prostatic hyperplasia (BPH).

  • Expected Therapeutic Effects: Significant lowering of standing and supine blood pressure; increased peak urinary flow rate with reduced hesitancy in BPH.

  • Adverse Reactions & Side Effects:

    • First-Dose Phenomenon (Hallmark Hazard): Marked, acute orthostatic hypotension occurring within $30\text{ to }90\,\text{minutes}$ of the initial dose or rapid dose titration, causing sudden cerebral hypoperfusion and syncopal collapse (first-dose syncope).

    • Common Side Effects: Dizziness, headache, drowsiness, weakness, dry mouth, nausea, palpitations, fluid retention, and dependent peripheral edema.

    • Severe & Life-Threatening: Syncopal loss of consciousness with head trauma; prolonged, painful erection (priapism requiring emergent surgical decompression).

  • Contraindications, Cautions & Nursing Checks:

    • Contraindications: Known hypersensitivity; absolute prohibition of concurrent phosphodiesterase-5 (PDE-5) inhibitors (sildenafil) due to profound, fatal synergistic hypotension.

    • Cautions: Pre-existing orthostatic hypotension, angina pectoris, ocular surgery (intraoperative floppy iris syndrome), renal impairment, and pregnancy.

    • Checks: Measure baseline supine and standing blood pressures; evaluate fall risk; ensure first dose is administered strictly at bedtime while client is recumbent.

    • Interactions: Additive hypotension when combined with nitrates, ethanol, diuretics, ACE inhibitors, or calcium channel blockers; NSAIDs blunt blood pressure lowering efficacy.

  • Patient Education:

    • Take the initial dose (and any upward dose adjustments) strictly at bedtime while in bed to minimize syncopal fall risks.

    • Change positions slowly: sit on edge of bed for several minutes before standing.

    • Avoid alcohol binges, hot showers, and strenuous exercise, which aggravate orthostasis.

    • Do not take OTC cough, cold, or allergy decongestants (pseudoephedrine, phenylephrine) without provider consultation, as sympathomimetics counteract prazosin.

    • Immediately seek emergency medical attention if an erection lasts longer than $4\,\text{hours}$.

  • Memory Hooks: "-osin = alpha-1 blocker"; "Pass-out-osin" (first dose at bedtime); "Prazosin + Viagra = No."

• Lisinopril (Prinivil / Zestril)

  • Classification: Angiotensin-converting enzyme (ACE) inhibitor.

  • Mechanism of Action: Competitively inhibits angiotensin-converting enzyme (kininase II), blocking the enzymatic conversion of angiotensin I to the potent vasoconstrictor angiotensin II; results in systemic arterial vasodilation and decreased peripheral vascular resistance; decreases aldosterone secretion, promoting renal excretion of sodium and water while retaining potassium; inhibits the degradation of bradykinin, leading to elevated bradykinin tissue levels (which triggers vasodilation, but also the characteristic dry cough and angioedema); provides renal microvascular protection by reducing intraglomerular capillary pressure in diabetic nephropathy.

  • Indications & Uses: Essential hypertension; adjunctive management of heart failure with reduced ejection fraction; post-myocardial infarction hemodynamics (within $24\,\text{hours}$ of acute MI to improve survival); slow progression of diabetic nephropathy.

  • Expected Therapeutic Effects: Lowering of systemic blood pressure, reduction in preload and afterload, preservation of renal function in microalbuminuria, and improved long-term post-MI survival.

  • Adverse Reactions & Side Effects:

    • Respiratory Hallmark: Persistent, tickling, nonproductive, dry cough ("ACE cough") that is refractory to cough suppressants and resolves only upon drug cessation.

    • Common Side Effects: Dizziness, postural hypotension, fatigue, headache, nausea, and diarrhea.

    • Severe & Life-Threatening: Fatal angioedema (rapid, non-pitting edema involving the subcutaneous tissue of the face, lips, tongue, glottis, and larynx presenting as acute airway obstruction); severe hyperkalemia ($K^+ \ge 5.5\,\text{mEq/L}$); acute renal failure (particularly in clients with bilateral renal artery stenosis); and black-box teratogenic fetopathy (fetal hypotension, renal agenesis, oligohydramnios, skeletal deformations, and intrauterine death).

  • Contraindications, Cautions & Nursing Checks:

    • Contraindications: Pregnancy (strictly contraindicated in the second and third trimesters; black-box warning), history of hereditary or ACE-inhibitor-induced angioedema, and concurrent use with aliskiren in diabetic patients.

    • Hold Parameters: Check blood pressure before each dose; obtain baseline serum creatinine, BUN, and potassium; repeat BMP $1\text{ to }2\,\text{weeks}$ following drug initiation or upward titration; hold if serum potassium is $K^+ \ge 5.5\,\text{mEq/L}$ or acute renal failure manifests.

    • Interactions: Potassium supplements, spironolactone, triamterene, and salt substitutes cause lethal hyperkalemia; NSAIDs inhibit vasodilatory prostaglandins, decreasing antihypertensive efficacy and inducing acute kidney injury; combination with ARBs (valsartan) increases toxic renal risks without therapeutic benefit.

  • Patient Education:

    • Immediately seek emergency medical attention if swelling of the lips, face, tongue, or difficulty breathing/swallowing occurs; permanently discontinue drug.

    • Do not consume potassium supplements or potassium-containing salt substitutes.

    • Report the onset of a dry, persistent cough; do not discontinue medication without provider approval.

    • Females of childbearing age must notify provider immediately if pregnancy is suspected; discontinue medication immediately.

  • Memory Hooks: "-PRIL = Pregnancy no, Raised K, Itchy dry cough, Lip swelling"; "BP first, then pill."

• Valsartan (Diovan)

  • Classification: Angiotensin II receptor blocker (ARB).

  • Mechanism of Action: Selectively and competitively blocks the binding of angiotensin II to angiotensin type 1 ($AT_1$) receptors located in vascular smooth muscle, the adrenal gland, and myocardial tissue; blocks angiotensin II-mediated vasoconstriction and aldosterone release without inhibiting ACE or blocking bradykinin degradation; produces systemic vasodilation and renal sodium/water excretion without the high incidence of bradykinin-mediated dry cough.

  • Indications & Uses: Essential hypertension; chronic heart failure (NYHA class II-IV) in patients who are intolerant of ACE inhibitors; reduction of cardiovascular mortality following acute myocardial infarction.

  • Expected Therapeutic Effects: Sustained lowering of arterial blood pressure; improvement in congestive heart failure symptoms with minimal incidence of cough.

  • Adverse Reactions & Side Effects:

    • Common Side Effects: Dizziness, fatigue, headache, orthostatic hypotension, diarrhea, abdominal pain, back pain, arthralgia, and erectile dysfunction.

    • Severe & Life-Threatening: Angioedema (lower incidence than with ACE inhibitors, but cross-sensitivity can occur), severe hyperkalemia, acute renal impairment, neutropenia, rhabdomyolysis, and profound fetal toxicity / intrauterine demise.

  • Contraindications, Cautions & Nursing Checks:

    • Contraindications: Pregnancy (black-box warning for fetal toxicity); history of angioedema; concurrent therapy with an ACE inhibitor (lisinopril) is clinically prohibited due to heightened risk of hyperkalemia and renal failure.

    • Follow-up Red Flags: Follow up immediately if serum potassium is elevated (e.g., $K^+ = 5.6\,\text{mEq/L}$), if client is concurrently taking an ACE inhibitor, if client is pregnant, or if salt substitutes are being used.

    • Laboratory Monitoring: Monitor blood pressure, baseline serum creatinine, BUN, and potassium ($K^+$) prior to therapy and regularly during maintenance.

  • Patient Education:

    • Maintain a weekly blood pressure log and bring to clinic appointments.

    • Avoid potassium-containing salt substitutes and potassium supplements.

    • Discontinue medication immediately and notify provider if pregnancy occurs.

    • Change positions slowly to prevent dizziness.

  • Memory Hooks: "-SARTAN = ARB, 'Safer' (less cough)"; "Never pair PRIL with SARTAN."

Hematologic and Peripheral Vascular Pharmacotherapy (Topic 8)

• Four Pillars of Clot Pharmacology:

  • Anticoagulants: Prevent the formation of new fibrin clots and prevent the propagation/extension of existing thrombi; do not dissolve formed fibrin clots.

  • Antiplatelets: Inhibit platelet adhesion, activation, and aggregation in the arterial vasculature; prevent arterial thrombi and stent thrombosis; do not dissolve existing clots.

  • Thrombolytics ("Clot Busters"): Digest and dissolve established fibrin meshes; time-critical emergency intervention.

  • Antihyperlipidemics: Inhibit cholesterol synthesis and stabilize atheromatous plaques.

• Heparin (Unfractionated Heparin - UFH)

  • Classification: Indirect thrombin inhibitor; parenteral anticoagulant.

  • Mechanism of Action: Binds to and induces a conformational change in antithrombin III (ATIII), accelerating its inhibitory action by over $1{,}000\text{-fold}$; the heparin-ATIII complex rapidly inactivates factor IIa (thrombin), factor Xa, and factors IXa, XIa, and XIIa; prevents conversion of fibrinogen to fibrin, preventing clot formation and propagation. Does not dissolve established thrombi.

  • Indications & Uses: Prophylaxis and treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE); acute coronary syndromes (unstable angina, NSTEMI, STEMI); percutaneous coronary intervention (PCI); cardiopulmonary bypass surgery; maintenance of patency in arterial/venous catheters; acute management of disseminated intravascular coagulation (DIC).

  • Routes of Administration: Continuous IV infusion for therapeutic anticoagulation; subcutaneous injection (SQ) for low-dose prophylaxis; strictly prohibited via intramuscular (IM) injection due to catastrophic hematoma risk.

  • Expected Therapeutic Effects: Prevention of thrombus formation and propagation; maintenance of therapeutic anticoagulation evidenced by therapeutic activated partial thromboplastin time (aPTT).

  • Adverse Reactions & Side Effects:

    • Common Side Effects: Injection site hematoma, irritation, local erythema, chills, fever, pruritus, and elevated hepatic transaminases.

    • Severe & Life-Threatening: Fatal internal and external hemorrhage; hemorrhagic stroke; Heparin-Induced Thrombocytopenia (HIT Type II: an immune-mediated disorder caused by IgG antibodies directed against the heparin-platelet factor 4 complex, precipitating massive platelet activation, catastrophic paradoxical arterial/venous thrombosis, and marked drop in platelet counts by $\ge 50\%$).

  • Contraindications, Cautions & Nursing Checks:

    • Contraindications: Uncontrolled active internal bleeding, history of confirmed Heparin-Induced Thrombocytopenia (HIT), severe thrombocytopenia, severe hemophilia, and suspected intracranial hemorrhage.

    • Cautions: Peptic ulcer disease (PUD), severe hepatic or renal dysfunction, recent brain, eye, or spinal cord surgery, severe uncontrolled hypertension, and lumbar puncture.

    • Laboratory Monitoring & Hold Parameters: Monitor activated partial thromboplastin time (aPTT) closely (therapeutic target is generally $1.5\text{ to }2.5\,\text{times}$ baseline normal control, or approximately $60\text{ to }80\,\text{seconds}$; hold infusion and alert provider if aPTT is supratherapeutic); baseline and serial platelet counts every $2\text{ to }3\,\text{days}$ (immediately discontinue all heparin products and suspect HIT if platelets precipitously drop by $\ge 50\%$ or fall below $100{,}000/\mu\text{L}$; never give platelets during acute HIT without hematology clearance).

    • Interactions: Markedly enhanced hemorrhage risk with aspirin, NSAIDs, clopidogrel, direct oral anticoagulants, and thrombolytics; IV nitroglycerin can decrease heparin anticoagulant efficacy; goldenseal decreases heparin effect.

  • Antidote: Protamine Sulfate. Administer by slow, controlled IV push (not exceeding $50\,\text{mg}$ in a $10\text{-minute}$ period); rapid infusion causes sudden hypotension, severe bradycardia, and anaphylactoid collapse.

  • Patient Education:

    • Use a soft-bristle toothbrush and electric razor to prevent mucosal and cutaneous trauma.

    • Avoid self-administering OTC aspirin, ibuprofen, or other NSAIDs.

    • Report sudden nosebleeds (epistaxis), bleeding gums, hematuria, coffee-ground emesis, black tarry stools, or unusual bruising.

    • Wear or carry a medical alert identification tag denoting anticoagulant therapy.

  • Memory Hooks: "Hep = aPTT"; "Protamine Pro-tects from heparin"; "Platelets plummet = HIT."

• Enoxaparin (Lovenox)

  • Classification: Low-molecular-weight heparin (LMWH).

  • Mechanism of Action: Produced by chemical or enzymatic depolymerization of unfractionated heparin; binds antithrombin III and preferentially accelerates the inactivation of factor Xa with minimal inhibitory activity against thrombin (factor IIa); prevents conversion of prothrombin to thrombin.

  • Indications & Uses: Prevention of postoperative DVT/PE following orthopedic (total hip/knee replacement) or abdominal surgery; inpatient and outpatient treatment of acute DVT and PE; prevention of ischemic complications in unstable angina, NSTEMI, and STEMI.

  • Expected Therapeutic Effects: Prevention of venous thromboembolism without the requirement for frequent laboratory coagulation titration.

  • Adverse Reactions & Side Effects:

    • Common Side Effects: Injection site hematoma, local pain, mild anemia, transient fever, peripheral edema, and mild elevation of liver enzymes.

    • Severe & Life-Threatening: Major systemic hemorrhage; epidural or spinal hematoma (causing permanent paralysis following neuraxial anesthesia or lumbar puncture; black-box warning); Heparin-Induced Thrombocytopenia (HIT; lower risk than with UFH, but absolute cross-reactivity exists).

  • Contraindications, Cautions & Nursing Checks:

    • Contraindications: Active major bleeding, history of immune-mediated HIT, and severe hypersensitivity to heparin or pork products.

    • Laboratory Monitoring: Routine daily coagulation monitoring (PT, aPTT) is not required due to predictable bioavailability; periodic baseline CBC, platelet counts, and serum creatinine are indicated.

    • Subcutaneous Administration Technique: Administer strictly via subcutaneous (SQ) injection into the anterolateral or posterolateral abdominal wall ("love the belly"), at least $2\,\text{inches}$ away from the umbilicus; alternate left and right sides daily; do NOT expel the prefilled manufactured nitrogen air bubble from the syringe prior to injection (the bubble clears the needle and creates a seal to prevent drug tracking into subcutaneous tissue); pinch skin fold, insert needle fully at a $90^\circ$ angle, and inject slowly; do NOT rub or massage the injection site afterwards (causes hematomas); NEVER inject IM.

  • Antidote: Protamine Sulfate provides only partial reversal (approximately $60\%\text{ to }75\%$ of anti-Xa activity is neutralized).

  • Patient Education:

    • Demonstrate correct self-injection technique into abdominal fat pad, retaining the air bubble and avoiding rubbing.

    • Maintain standard bleeding precautions: soft toothbrush, electric razor, avoidance of OTC NSAIDs.

    • Report red or dark brown urine, black tarry stools, severe dizziness, or spontaneous bruising.

  • Memory Hooks: Lovenox = "Love the belly" (SQ abdomen, bubble stays); "Xa = ten-A"; "No routine PTT checks."

• Warfarin Sodium (Coumadin)

  • Classification: Oral anticoagulant; synthetic vitamin K antagonist (coumarin derivative).

  • Mechanism of Action: Competitively inhibits the hepatic enzyme vitamin K epoxide reductase complex 1 (VKORC1); completely blocks the active regeneration of reduced vitamin K (vitamin KH2), thereby suppressing the hepatic post-translational carboxylation of functional clotting factors II (prothrombin), VII, IX, and X, as well as endogenous regulatory anticoagulant proteins C and S; clinical anticoagulant onset is delayed ($36\text{ to }72\,\text{hours}$) while existing circulating clotting factors decay according to their half-lives (factor VII clears first; prothrombin factor II clears last over $60\,\text{hours}$).

  • Indications & Uses: Long-term outpatient prophylaxis and management of venous thrombosis, pulmonary embolism, and thromboembolism associated with chronic atrial fibrillation; prevention of mechanical and bioprosthetic heart valve thrombosis.

  • Coagulation Monitoring & Target INR Values:

    • Dosed to achieve a specific target International Normalized Ratio (INR), calculated from the Prothrombin Time (PT).

    • Standard Target INR: $2.0\text{ to }3.0$ for general DVT, PE, and atrial fibrillation management.

    • High-Intensity Target INR: $2.5\text{ to }3.5$ for mechanical prosthetic heart valves and recurrent systemic embolism.

  • Adverse Reactions & Side Effects:

    • Common Side Effects: Gastrointestinal distress, nausea, anorexia, transient alopecia, chills, fever, headache, and weakness.

    • Severe & Life-Threatening: Fatal systemic hemorrhage; intracranial hemorrhage; microembolization syndrome ("purple-toe syndrome" manifesting as painful, blue-purple discoloration of the toes caused by mobilized cholesterol crystals); warfarin-induced skin necrosis (rapid fall in protein C); and increased risk of bone fractures with chronic use.

  • Contraindications, Cautions & Nursing Checks:

    • Contraindications: Pregnancy (crosses the placenta causing fatal embryopathy, chondrodysplasia punctata, and catastrophic fetal hemorrhage; strictly contraindicated; black-box warning), active internal bleeding, open ulcerative lesions, severe alcoholism, malignant hypertension, and neurosurgical/ophthalmic procedures.

    • Checks: Daily INR monitoring until therapeutic and stable, then weekly to monthly; baseline platelet counts; visual inspection of mucous membranes, urine, stool, and skin.

    • Drug and Food Interactions: Drugs that enhance warfarin effect (elevate INR and bleeding): broad-spectrum antibiotics (eliminate vitamin K-producing gut bacteria), aspirin, NSAIDs, sulfonamides, cimetidine, allopurinol, amiodarone, and vitamin E. Drugs that decrease warfarin effect (lower INR and risk thrombosis): barbiturates, carbamazepine, rifampin, phenytoin, oral contraceptives, high-dose vitamin C, and dietary vitamin K.

  • Antidote: Vitamin K1 (Phytonadione) reverses warfarin; administered orally or by slow IV infusion. In the setting of catastrophic or life-threatening hemorrhage, immediately administer Prothrombin Complex Concentrate (PCC / Kcentra) or Fresh Frozen Plasma (FFP) along with IV vitamin K to instantly restore clotting factors.

  • Patient Education:

    • Take at the exact same time every day, preferably in the evening.

    • Maintain a strictly CONSISTENT daily dietary intake of vitamin K-rich foods (green leafy vegetables such as spinach, kale, collard greens, broccoli, Brussels sprouts); do NOT eliminate greens, but avoid sudden increases or decreases in consumption.

    • Never consume binge alcohol; avoid all OTC aspirin and NSAIDs unless specifically cleared by provider.

    • Inform dentists and all surgical specialists of warfarin therapy well before procedures.

    • Wear a permanent MedicAlert bracelet.

  • Memory Hooks: "War on clots, INR 2 to 3"; "Vitamin K is the peace treaty"; "Greens: be consistent, not forbidden."

• Clopidogrel Bisulfate (Plavix)

  • Classification: Antiplatelet agent; thienopyridine adenosine diphosphate (ADP) / $P2Y_{12}$ receptor antagonist.

  • Mechanism of Action: An inactive prodrug requiring hepatic biotransformation by cytochrome P450 enzymes (predominantly CYP2C19) into an active thiol metabolite; the active metabolite selectively and irreversibly blocks the binding of adenosine diphosphate (ADP) to its platelet $P2Y_{12}$ purinergic receptor; prevents downstream ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, irreversibly inhibiting platelet activation and aggregation for the lifespan of the platelet ($7\text{ to }10\,\text{days}$).

  • Indications & Uses: Reduction of atherothrombotic events in clients with recent myocardial infarction, recent ischemic stroke, or established peripheral arterial disease (PAD); treatment of acute coronary syndromes (unstable angina, NSTEMI, STEMI); prevention of subacute stent thrombosis following percutaneous coronary intervention (PCI) and coronary stenting.

  • Expected Therapeutic Effects: Significant reduction in combined rates of ischemic stroke, systemic MI, and vascular death in high-risk arterial vascular clients.

  • Adverse Reactions & Side Effects:

    • Common Side Effects: Dyspepsia, abdominal pain, diarrhea, nausea, dizziness, headache, minor epistaxis, purpura, and skin rash.

    • Severe & Life-Threatening: Fatal internal bleeding (major gastrointestinal and intracranial hemorrhage); Thrombotic Thrombocytopenic Purpura (TTP: marked by microangiopathic hemolytic anemia, profound thrombocytopenia, neurological abnormalities, fever, and renal impairment; requires emergent plasmapheresis); severe agranulocytosis; aplastic anemia; and Stevens-Johnson syndrome.

  • Contraindications, Cautions & Nursing Checks:

    • Contraindications: Active pathological bleeding, such as peptic ulcer disease or acute intracranial hemorrhage.

    • Cautions: Renal/hepatic dysfunction, planned elective surgical procedures (must discontinue $5\text{ to }7\,\text{days}$ prior to major surgery to avoid catastrophic intraoperative blood loss).

    • Checks: Baseline CBC, complete platelet count, screening for occult gastrointestinal blood loss, and monitoring for TTP clinical cues (fever, sudden neurological confusion, purpura).

    • CYP2C19 Interactions: Omeprazole and esomeprazole are potent CYP2C19 inhibitors that significantly decrease metabolic activation of clopidogrel, elevating stent thrombosis and reinfarction risk; if a proton pump inhibitor (PPI) is required for gastroprotection, select Pantoprazole; avoid grapefruit juice (inhibits CYP-mediated activation).

  • Antidote: No specific pharmacologic antidote; in emergency life-threatening bleeding or urgent surgical procedures, administer donor Platelet Transfusions.

  • Patient Education:

    • Take once daily with or without food; take with meals if gastrointestinal upset occurs.

    • Avoid grapefruit juice and avoid all OTC NSAIDs (ibuprofen, naproxen) and aspirin without authorization.

    • Promptly report black tarry stools, bloody emesis, unexplained hematomas, fever, or confusion.

  • Memory Hooks: "Plavix = Platelets Apart"; "CLOt stOPper"; "Pick pantoprazole, not omeprazole."

• Aspirin (Low-Dose, 81 mg / Bayer Aspirin / Acetylsalicylic Acid)

  • Classification: Antiplatelet; irreversible cyclooxygenase (COX-1) inhibitor; nonsteroidal anti-inflammatory salicylate.

  • Mechanism of Action: Irreversibly acetylates and inactivates the cyclooxygenase-1 (COX-1) enzyme within circulating platelets; permanently prevents the conversion of arachidonic acid to thromboxane $A_2$ ($TXA_2$), a potent pro-aggregatory lipid and peripheral vasoconstrictor; platelet COX-1 remains blocked for the functional life of the platelet ($7\text{ to }10\,\text{days}$) because platelets lack nuclei and cannot synthesize new proteins; prevents new clot formation.

  • Indications & Uses: Primary prevention of atherosclerotic cardiovascular disease in high-risk individuals; secondary prevention of recurrent ischemic stroke, transient ischemic attacks (TIAs), and acute myocardial infarction; cornerstone immediate emergency pharmacotherapy chewed during acute evolving MI to minimize infarct size.

  • Dose Distinction Hallmark: At the low dose of $81\,\text{mg daily}$, aspirin functions solely to prevent new clot formation. It does NOT dissolve pre-existing fibrin clots and does NOT provide analgesia or systemic anti-inflammatory relief.

  • Adverse Reactions & Side Effects:

    • Common Side Effects: Dyspepsia, epigastric distress, heartburn, nausea, and minor bruising.

    • Severe & Life-Threatening: Serious upper gastrointestinal ulceration and major GI hemorrhage; hemorrhagic stroke; salicylate toxicity (tinnitus, metabolic acidosis at higher doses).

  • Contraindications, Cautions & Nursing Checks:

    • Contraindications: Active bleeding disorders, advanced peptic ulcer disease, and known aspirin/NSAID-induced asthma or anaphylaxis.

    • Cautions: Co-administration with other systemic anticoagulants (heparin, warfarin) markedly elevates major bleeding risk.

  • Patient Education:

    • Take daily with food and a full glass of water to reduce mucosal irritation.

    • Do not supplement with OTC NSAIDs (ibuprofen) because they can competitively block aspirin's access to the platelet COX-1 binding site, blunting cardioprotection.

    • Report black tarry stools, persistent stomach ache, or frequent nosebleeds.

  • Memory Hooks: "81 = prevent, not dissolve"; "Aspirin early in MI saves lives."

• Alteplase (tPA / Activase)

  • Classification: Thrombolytic agent; recombinant tissue-type plasminogen activator (rtPA).

  • Mechanism of Action: Directly binds to fibrin within an established thrombus; converts inactive entrapped plasminogen into active plasmin; plasmin degrades the cross-linked fibrin matrix of the clot, lysing the thrombus and rapidly restoring ischemic vascular perfusion (fibrinolysis). The ONLY drug class that actively dissolves existing clots.

  • Indications & Critical Time Windows ("Time is Tissue"):

    • Acute Ischemic Stroke: Administer within $3\text{ to }4.5\,\text{hours}$ of symptom onset / last known normal.

    • Acute Myocardial Infarction (STEMI): Administer within $\approx 30\,\text{minutes}$ of hospital arrival ("door-to-needle" time).

    • Massive acute pulmonary embolism (PE) with hemodynamic instability.

    • Restoration of patency in occluded central venous access devices (Cathflo formulation).

  • Adverse Reactions & Side Effects:

    • Common Side Effects: Superficial puncture site oozing, epistaxis, gingival bleeding, nausea, vomiting, mild fever, and localized hematomas.

    • Severe & Life-Threatening: Catastrophic intracranial hemorrhage (ICH; manifests as sudden mental status decline, pupillary changes, severe headache), retroperitoneal internal bleeding, reperfusion dysrhythmias (ventricular tachycardia), angioedema (higher incidence in stroke patients on concurrent ACE inhibitors), and anaphylaxis.

  • Contraindications, Cautions & Nursing Checks:

    • Absolute Contraindications: Active internal bleeding, history of recent cerebrovascular accident, intracranial neoplasm, arteriovenous malformation or aneurysm, recent intracranial or intraspinal surgery or serious trauma within $3\,\text{months}$, severe uncontrolled hypertension ($SBP > 185\,\text{mmHg}$ or $DBP > 110\,\text{mmHg}$ refractory to IV antihypertensives), and suspected aortic dissection.

    • Pre-Administration Assessment: Baseline CBC, PT/INR, aPTT, platelet count, blood type and screen, baseline 12-lead ECG, and baseline neurological score (NIH Stroke Scale).

    • Post-Infusion Protocol Checks: Strict vital sign and neurological assessments every $15\,\text{minutes}$ during the first hour, every $30\,\text{minutes}$ for the next $7\,\text{hours}$, and then every $1\,\text{hour}$ until completion of $24\,\text{hours}$ post-infusion (the "15-30-60" monitoring schedule); maintain strict bleeding precautions for a full $24\,\text{hours}$; do NOT perform venipunctures, arterial lines, or insert nasogastric tubes or urinary catheters during the bleeding precaution window.

    • Nursing Diagnoses: Decreased Cardiac Output related to internal hemorrhage; Risk for Impaired Tissue Integrity.

  • Antidote: Aminocaproic Acid (Amicar). Serves as a direct competitive inhibitor of plasminogen activation and fibrinolysis to arrest catastrophic hemorrhage.

  • Patient Education:

    • Remain strictly on complete bed rest during administration.

    • Immediately report sudden headache, dizziness, nausea, palpitations, itching, or confusion.

  • Memory Hooks: "ALTEr the clot = dissolves it"; "Aminocaproic acid (A to A)"; "Checks: 15-30-60."

• Atorvastatin (Lipitor)

  • Classification: Antihyperlipidemic; 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor ("statin").

  • Mechanism of Action: Competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in hepatic cholesterol biosynthesis; decreases intracellular hepatic cholesterol, upregulating cell-surface low-density lipoprotein (LDL) receptors; accelerates systemic LDL clearance; significantly lowers circulating total cholesterol, LDL, and triglycerides ($\downarrow LDL, \downarrow TG$) while producing modest increases in high-density lipoprotein ($\uparrow HDL$); stabilizes vulnerable coronary atherosclerotic plaques, reduces vascular inflammation, and improves endothelial function.

  • Indications & Uses: Primary and secondary prevention of atherosclerotic cardiovascular disease (ASCVD), reducing risk of MI, stroke, and revascularization; management of primary hypercholesterolemia, mixed dyslipidemia, and hypertriglyceridemia.

  • Expected Therapeutic Effects: Marked sustained reduction in serum LDL and triglyceride levels; long-term prevention of cardiovascular morbidity.

  • Adverse Reactions & Side Effects:

    • Common Side Effects: Mild myalgias, arthralgia, headache, dyspepsia, abdominal cramps, diarrhea, nausea, and rash.

    • Severe & Life-Threatening: Rhabdomyolysis (skeletal muscle lysis releasing toxic myoglobin into the circulation, precipitating acute renal failure and death; characterized by severe diffuse muscle pain, tenderness, weakness, fever, and dark tea-colored or amber urine); acute drug-induced hepatitis and hepatotoxicity with marked elevation in serum ALT and AST.

  • Contraindications, Cautions & Nursing Checks:

    • Contraindications: Active hepatic disease, unexplained persistent elevations in liver enzymes, pregnancy (strictly contraindicated; statins interrupt embryological membrane and steroid development), and breastfeeding.

    • Cautions: Chronic alcoholism, renal impairment, and untreated hypothyroidism.

    • Monitoring: Baseline and serial lipid profiles, ALT, and AST; obtain serum creatine kinase (CK) levels if patient reports severe muscle soreness.

    • Interactions: Co-administration with strong CYP3A4 inhibitors (macrolide antibiotics such as clarithromycin, erythromycin; azole antifungals; HIV protease inhibitors) dramatically elevates atorvastatin plasma concentrations, increasing rhabdomyolysis risk.

  • Patient Education:

    • Immediately report unexplained muscle aches, tenderness, profound weakness, fatigue, or dark amber-colored urine.

    • Take once daily with water or with meals to alleviate stomach upset; the drug may be taken in the morning or evening.

    • Statin therapy is an adjunct, not a replacement: maintain a low-fat, low-cholesterol heart-healthy diet.

    • Do not stop taking the drug abruptly; sudden cessation can lead to a rebound surge in circulating lipids and vascular inflammation.

    • Schedule annual ophthalmology examinations due to increased risk of lens opacities/cataracts.

  • Memory Hooks: "-statin = Stops Synthesis"; "Mad Muscles = Rhabdo"; "Lipids and LFTs (ALT/AST)."

• Cilostazol (Pletal)

  • Classification: Direct-acting vasodilator; selective phosphodiesterase-3 (PDE-3) inhibitor with antiplatelet properties.

  • Mechanism of Action: Inhibits cellular phosphodiesterase type 3 (PDE-3), preventing the degradation of cyclic adenosine monophosphate (cAMP) in platelets and vascular smooth muscle; elevated cAMP suppresses platelet aggregation and induces direct arterial relaxation, preferentially dilating femoral and peripheral arterial beds; reduces peripheral vascular resistance and improves collateral arterial microcirculation in ischemic limbs.

  • Indications & Uses: Symptomatic management of peripheral artery disease (PAD) manifesting as intermittent claudication (ischemic calf muscle cramping pain precipitated by walking and relieved by rest).

  • Expected Therapeutic Effects: Gradual, sustained increase in pain-free walking distance and overall walking capacity. Onset of noticeable therapeutic benefit requires $1.5\text{ to }3\,\text{months}$ ($6\text{ to }12\,\text{weeks}$) of consistent administration.

  • Adverse Reactions & Side Effects:

    • Common Side Effects: Headache (very frequent), dizziness, dependent peripheral edema, diarrhea, dyspepsia, abdominal discomfort, back pain, and melena.

    • Severe & Life-Threatening: Tachycardia, palpitations, life-threatening ventricular dysrhythmias, serious blood dyscrasias (agranulocytosis, thrombocytopenia), and systemic bleeding.

  • Contraindications, Cautions & Nursing Checks:

    • Black-Box Absolute Contraindication: Strictly contraindicated in all clients with congestive heart failure of any severity; PDE-3 inhibitors possess inotropic properties that significantly increase long-term mortality in patients with heart failure.

    • Cautions: Bleeding disorders, active thrombocytopenia, severe hepatic or renal dysfunction, and concurrent tobacco smoking.

    • Checks: Assess bilateral lower-extremity peripheral perfusion (pedal pulses, capillary refill, skin color, temperature, ischemic pain scores); monitor baseline and maintenance liver transaminases and CBC.

    • Interactions: Green tea and grapefruit juice inhibit metabolism, significantly increasing drug levels; ginkgo potentiates bleeding; St. John's wort lowers drug concentrations.

  • Patient Education:

    • Administer on an empty stomach or with meals as directed by provider (taking with meals minimizes gastrointestinal distress).

    • Therapeutic response is slow: educate that improvements in walking distance will take $1.5\text{ to }3\,\text{months}$.

    • Stop smoking: nicotine causes severe peripheral arterial vasospasm, negating all therapeutic benefits of cilostazol.

    • Avoid alcohol; rise slowly from lying/sitting to prevent orthostatic dizziness.

    • Report dark tarry stools, easy bruising, or palpitations/irregular heartbeats.

  • Memory Hooks: "PLETal = PEDal/walk"; "Claudication calf cramps"; "No HF!"; "Smoking = spasm."

Comparative Pharmacotherapy and Shared Adverse Effects

• Respiratory Showdowns:

  • Rescue vs. Maintenance: Albuterol is the ONLY rescue bronchodilator for acute, emergent bronchospastic attacks. Tiotropium and Montelukast are strictly maintenance agents with slow, progressive onsets; they must never be used in acute emergencies.

  • Anticholinergic Synergy: Tiotropium and Diphenhydramine share the anticholinergic syndrome ("can't see, can't pee, can't spit, can't defecate"). Both are contraindicated or cautioned in BPH, narrow-angle glaucoma, and bladder neck obstruction.

  • CNS Depression & Misuse Risk: Diphenhydramine and Dextromethorphan induce additive sedation with alcohol or depressants; both carry high abuse potential among adolescents.

• Beta-Blocker Showdowns (Atenolol vs. Metoprolol):

  • Shared Characteristics: Cardioselective beta1 antagonism, "-olol" suffix, lower HR and BP, suppress renin, mask hypoglycemia symptoms (sweating remains intact), caution in reactive airway disease, contraindication in high-grade AV block and severe sinus bradycardia, and strict prohibition of abrupt discontinuation (rebound angina/hypertension).

  • Key Differences: Atenolol is renally cleared, contraindicated in pregnancy/lactation, blunted by NSAIDs, and requires baseline ECG. Metoprolol is hepatically cleared; Toprol-XL (succinate) is specifically approved for heart failure and must never be crushed; also used for rate control in AF/SVT.

• The Heart-Slowing Conduction Trio (Digoxin vs. Beta Blockers vs. Diltiazem):

  • All three slow heart rate and can induce severe sinus bradycardia and high-grade atrioventricular (AV) heart block.

  • The concurrent combination of Digoxin + Beta Blocker + Diltiazem constitutes the lethal "Heart-Block Trio" and must be avoided or monitored with continuous telemetry.

  • Digoxin is uniquely a positive inotrope ($\uparrow$ contractility) despite slowing rate; requires a $1\text{-minute}$ apical pulse check with a strict hold threshold ($HR < 60\,\text{beats/min}$).

  • Specific Antidotes:

    • Digoxin: Digoxin immune Fab.

    • Diltiazem: Calcium Chloride ($CaCl_2$) for hypotension/heart block; Atropine for bradycardia.

    • Beta Blockers: Atropine for bradycardia; IV Glucagon for overdose.

• Diuretic Showdowns (HCTZ vs. Furosemide vs. Spironolactone):

  • Site of Action: HCTZ = early distal convoluted tubule; Furosemide = thick ascending limb of the loop of Henle; Spironolactone = late distal tubule and cortical collecting duct.

  • Diuretic Potency: Furosemide (most potent, high-ceiling) > HCTZ (moderate) > Spironolactone (mild).

  • Potassium Flux: HCTZ causes $\downarrow K^+$; Furosemide causes marked $\downarrow\downarrow K^+$; Spironolactone causes $\uparrow K^+$ (hyperkalemia).

  • Calcium Handling: HCTZ saves calcium ($\uparrow Ca^{2+}$, hypercalcemia); Furosemide wastes calcium ($\downarrow Ca^{2+}$, "loops lose it all"); Spironolactone has no direct calcium effect.

  • Metabolic Effects: HCTZ and Furosemide both cause hyperglycemia and hyperuricemia (gout flares); Spironolactone does not alter glucose or uric acid.

  • Signature Adverse Effects: HCTZ = photosensitivity and "Hyper-G-L-U-C"; Furosemide = ototoxicity (rapid IV) and acute volume collapse; Spironolactone = endocrine disturbances (gynecomastia).

  • Hold Parameters: HCTZ: $SBP < 90\,\text{mmHg}$ or symptomatic; Furosemide: $UO < 30\,\text{mL/h}$ or weight change $\ge 1\,\text{kg/24 h}$; Spironolactone: $K^+ \ge 5.5\,\text{mEq/L}$ or rising creatinine.

• RAAS Showdowns (Lisinopril vs. Valsartan):

  • Shared Risks: Contraindicated in pregnancy (black-box teratogenicity), cause hyperkalemia, cause angioedema, induce renal impairment, require routine monitoring of $K^+$ and creatinine, and must NEVER be combined concurrently.

  • Key Differences: Lisinopril causes persistent dry cough due to bradykinin accumulation; Valsartan blocks the receptor directly, avoids bradykinin accumulation, and causes significantly less cough ("safer"). Valsartan also lists neutropenia and rhabdomyolysis risks.

• Hypotension Hazard Showdowns:

  • Nitroglycerin and Prazosin are both strictly contraindicated with PDE-5 inhibitors (sildenafil/Viagra) due to fatal circulatory collapse.

  • Prazosin's primary hazard is first-dose syncope (requires bedtime dosing); Nitroglycerin's primary hold is $SBP < 90\,\text{mmHg}$.

• Anticoagulants vs. Antiplatelets vs. Thrombolytics:

  • Anticoagulants (Heparin, Enoxaparin, Warfarin): Prevent the formation of new fibrin clots and extension of existing clots; do NOT dissolve existing clots.

  • Antiplatelets (Clopidogrel, Aspirin 81 mg, Cilostazol): Inhibit platelet aggregation in arterial vasculature; do NOT dissolve existing clots.

  • Thrombolytic (Alteplase): The ONLY agent that actively dissolves and lyses existing cross-linked fibrin clots.

• Comprehensive Shared Adverse Effects Master Grid:

  • Systemic Bleeding / Hemorrhage: Heparin, Enoxaparin, Warfarin, Clopidogrel, Aspirin, Alteplase, Cilostazol.

  • Sinus Bradycardia / Conduction Heart Block: Digoxin, Atenolol, Metoprolol, Diltiazem.

  • Severe Hypotension / Postural Dizziness: Nitroglycerin, Atenolol, Metoprolol, Diltiazem, Hydrochlorothiazide, Furosemide, Spironolactone, Prazosin (first-dose syncope), Lisinopril, Valsartan, Cilostazol.

  • Hypokalemia ($\downarrow K^+$): Albuterol, Hydrochlorothiazide, Furosemide.

  • Hyperkalemia ($\uparrow K^+$): Spironolactone, Lisinopril, Valsartan.

  • Hyperglycemia ($\uparrow \text{Glucose}$): Hydrochlorothiazide, Furosemide (Albuterol causes transient elevation; caution in DM).

  • Masking of Hypoglycemia Symptoms: Atenolol, Metoprolol (sweating remains unmasked).

  • Hyperuricemia / Acute Gout: Hydrochlorothiazide, Furosemide.

  • Angioedema / Facial Swelling: Lisinopril, Valsartan, Albuterol, Tiotropium, Montelukast, Alteplase (Nitroglycerin causes localized lip/facial edema).

  • Classic Anticholinergic Syndrome (Dry mouth, urinary retention, blurred vision, constipation): Diphenhydramine, Tiotropium.

  • Drowsiness / Significant CNS Depression: Diphenhydramine, Dextromethorphan, Montelukast.

  • Cardiac Dysrhythmias: Albuterol, Tiotropium, Digoxin, Diltiazem, Cilostazol, Atenolol, Alteplase.

  • Rhabdomyolysis / Severe Muscle Lysis: Atorvastatin, Valsartan, Alteplase.

  • Elevated Hepatic Transaminases (LFTs): Heparin, Enoxaparin, Warfarin, Clopidogrel, Cilostazol, Atorvastatin (Montelukast requires LFT monitoring).

  • Thrombocytopenia / Severe Blood Dyscrasias: Diphenhydramine, Montelukast, Digoxin, Atenolol, Heparin (HIT), Clopidogrel (TTP), Hydrochlorothiazide, Furosemide, Cilostazol.

  • Stevens-Johnson Syndrome (SJS): Albuterol, Montelukast, Hydrochlorothiazide, Furosemide, Spironolactone, Clopidogrel.

  • Severe Mood Disturbance / Depression: Montelukast (suicidal ideation and behaviors), Atenolol and Metoprolol (depressive episodes).

  • Vascular Headache: Nitroglycerin (most common adverse effect), Cilostazol.

  • Ototoxicity & Tinnitus: Furosemide (rapid IV administration).

  • Cutaneous Photosensitivity: Hydrochlorothiazide.

  • Endocrine Gynecomastia: Spironolactone.

  • Persistent Nonproductive Dry Cough: Lisinopril.

  • Skeletal Muscle Tremors: Albuterol.

• Hold-Before-Giving Reference:

  • Digoxin: Auscultate apical pulse for $1\text{ full minute}$; HOLD if $HR < 60\,\text{beats/min}$.

  • Nitroglycerin: Check blood pressure; HOLD if $SBP < 90\,\text{mmHg}$.

  • Beta Blockers (Atenolol, Metoprolol): Check baseline parameters; HOLD if $HR < 60\,\text{beats/min}$ or $SBP < 90\,\text{mmHg}$.

  • Hydrochlorothiazide: Check BP and symptoms; HOLD if $SBP < 90\,\text{mmHg}$ or client is symptomatic.

  • Furosemide: Assess urine output and weight; notify provider if $UO < 30\,\text{mL/h}$ or body weight changes $\ge 1\,\text{kg/24 h}$.

  • Spironolactone: Check serum potassium; HOLD if $K^+ \ge 5.5\,\text{mEq/L}$ or serum creatinine is actively rising.

  • ACE Inhibitors / ARBs: Check blood pressure, potassium, and creatinine; HOLD if hypotensive, hyperkalemic ($K^+ \ge 5.5\,\text{mEq/L}$), or pregnant.

  • Heparin: Check coagulation panel; HOLD continuous infusion if aPTT is supratherapeutic.

  • Warfarin: Check INR prior to administration; hold and evaluate if INR is supratherapeutic ($> 3.0$ for standard, $> 3.5$ for mechanical valves).

• Pharmacologic Antidotes & Reversal Agents:

  • Digoxin: Digoxin immune Fab (Digibind / DigiFab).

  • Heparin: Protamine Sulfate (slow IV infusion).

  • Enoxaparin (LMWH): Protamine Sulfate (partial reversal, $\approx 60\%\text{ to }75\%$).

  • Warfarin: Vitamin K1 (Phytonadione); Prothrombin Complex Concentrate (PCC) or Fresh Frozen Plasma (FFP) for acute severe hemorrhage.

  • Alteplase: Aminocaproic Acid (Amicar).

  • Diltiazem (CCB): Calcium Chloride ($CaCl_2$) for hypotension and AV block; Atropine for bradycardia.

  • Beta Blockers: Atropine for bradycardia; IV Glucagon for refractory overdose.

  • Diuretics, ACE Inhibitors, ARBs, Statins: No specific pharmacologic antidote; discontinue drug, administer supportive therapy, and replace or eliminate electrolytes.

Complementary and Alternative Medicine (CAM) and Herb-Drug Interactions

• The 8 Functional Herb-Drug Memory Buckets:

  • Bucket 1: Blood Thinners ("4 G's + FCH"): Garlic, Ginger, Ginkgo, Green tea + Feverfew, Chamomile, Hawthorn (plus Omega-3 fatty acids with thrombolytics). Promotes severe platelet dysfunction and fibrinolytic activity, dramatically elevating bleeding risk when combined with heparin, enoxaparin, warfarin, clopidogrel, aspirin, cilostazol, or alteplase.

  • Bucket 2: Anticoagulant Blockers ("GGVA" = Get Gone, Very Anti-): Ginseng, Goldenseal, Valerian, and excessive Anise. Interfere with anticoagulant efficacy, promoting therapeutic failure; Goldenseal specifically decreases the anticoagulant effect of heparin.

  • Bucket 3: Digoxin Toxicity Enhancers ("Gentle Hearts Lose All Energy"): Ginseng, Hawthorn, Licorice, Aloe, and Ephedra. Elevate digoxin toxicity (several accelerate renal potassium wasting, sensitizing the heart to digoxin).

  • Bucket 3b: Digoxin Weakening Agents ("SGP" = Sinks Dig's Power): St. John's wort, Goldenseal, and Psyllium. Interfere with absorption or induce clearance, significantly decreasing serum digoxin levels and therapeutic response.

  • Bucket 4: Potassium Depleters ("LAB"): Licorice, Aloe, and Black cohosh. Accelerate renal and GI potassium wasting ($\downarrow K^+$); potentiates hypokalemia induced by thiazides and loop diuretics, directly triggering fatal digoxin toxicity; Licorice also causes mineralocorticoid excess, worsening edema and hypertension.

  • Bucket 5: Blood Pressure Shifters ("PGHG drops, Licorice lifts"):

    • Drops Blood Pressure: Parsley, Goldenseal, Hawthorn, and Garlic (the latter specifically with diltiazem) produce additive hypotension with antihypertensives; Hawthorn potentiates loop diuretic hypotension and blunts compensatory mechanisms.

    • Lifts Blood Pressure: Licorice elevates BP and antagonizes antihypertensives; Ginkgo elevates BP when co-administered with thiazide diuretics.

  • Bucket 6: St. John's Wort Elimination ("MDDC" = My Drugs Don't Count): Montelukast, Diltiazem, Digoxin, and Cilostazol. St. John's wort induces CYP3A4 and P-glycoprotein, dramatically decreasing serum concentrations and clinical efficacy of all four drugs.

  • Bucket 7: Cardiac Activity Modulators ("EGM" = Everything Gets Muted): Ephedra, Ginseng, and Milk thistle. Ginseng and milk thistle blunt cardiac medications; Ephedra produces dangerous cardiac stimulation, elevating HR and BP, antagonizing cardiac meds, and triggering dysrhythmias when paired with albuterol.

  • Bucket 8: Teas, Grapefruit, and Vitamins ("E Enhances, K Kills"):

    • Green and Black Tea: Increases montelukast stimulation; green tea raises cilostazol levels; both increase systemic bleeding.

    • Grapefruit Juice: Inhibits CYP2C19/CYP3A4; decreases activation of clopidogrel (increasing clot risk); increases levels of cilostazol (elevating toxicity).

    • Vitamins: Vitamin E enhances warfarin efficacy and elevates bleeding risk; Vitamin K and Vitamin C decrease warfarin efficacy (maintain consistent dietary vitamin K intake).

• Herb-Drug Clinical Interaction Matrix:

  • Garlic: Enhances bleeding with heparin, warfarin, clopidogrel, alteplase; causes severe additive hypotension when combined with diltiazem.

  • Ginger: Enhances bleeding with all anticoagulants, antiplatelets, and clopidogrel.

  • Ginkgo: Enhances bleeding with anticoagulants, antiplatelets, cilostazol, alteplase; paradoxically increases blood pressure when paired with thiazides (HCTZ).

  • Green Tea: Increases montelukast CNS stimulation; elevates cilostazol concentrations; increases bleeding with blood thinners.

  • Feverfew: Enhances bleeding with heparin, warfarin, clopidogrel, alteplase.

  • Chamomile: Enhances bleeding with heparin, warfarin, alteplase.

  • Hawthorn: Lowers blood pressure, causing severe hypotension with antihypertensives (beta blockers, ACE inhibitors, diltiazem); potentiates loop diuretic hypotension; elevates digoxin toxicity; increases bleeding with anticoagulants.

  • Omega-3 Fatty Acids: Increases bleeding specifically with thrombolytic therapy (alteplase).

  • Goldenseal: Lowers blood pressure; decreases digoxin efficacy; directly decreases heparin efficacy; interferes with systemic anticoagulation.

  • Parsley: Promotes vasodilation, causing additive hypotension with antihypertensives.

  • Licorice: Accelerates potassium wasting ($\downarrow K^+$); increases digoxin toxicity; antagonizes all antihypertensives (raises BP); exacerbates fluid retention and peripheral edema.

  • Ginseng: Decreases the therapeutic effects of diltiazem and loop diuretics (furosemide); increases digoxin toxicity; interferes with warfarin and heparin anticoagulation.

  • Ephedra: Stimulates cardiac sympathetic receptors, causing marked tachycardia and dysrhythmias; antagonizes cardiac drugs; potentiates albuterol tachycardia; raises digoxin toxicity.

  • Milk Thistle: Decreases the pharmacological effectiveness of cardiac medications.

  • Aloe: Causes profound gastrointestinal potassium loss; accelerates hypokalemia with thiazides, inducing severe digoxin toxicity.

  • Black Cohosh: Causes accelerated potassium loss; potentiates diuretic-induced hypokalemia and digoxin toxicity.

  • Psyllium: Decreases enteral absorption and systemic availability of digoxin.

  • St. John's Wort: Accelerates hepatic metabolism, decreasing serum levels of montelukast, diltiazem, digoxin, and cilostazol.

  • Valerian / Anise: Interfere with anticoagulation parameters; decrease the efficacy of heparin and warfarin.

• The 4 Systematic Exam Inquiries for CAM Evaluation:

  1. Does the herb thin the blood? (Garlic, Ginger, Ginkgo, Green tea, Feverfew, Chamomile, Hawthorn, Omega-3).

  2. Does the herb move blood pressure up or down? (Down = Hawthorn, Parsley, Goldenseal, Garlic; Up = Licorice, Ginkgo with thiazides).

  3. Does the herb disrupt potassium or provoke digoxin toxicity? (Disrupts K = Licorice, Aloe, Black cohosh; Digoxin toxicity = Ginseng, Hawthorn, Licorice, Aloe, Ephedra).

  4. Does the herb block or eliminate drug concentrations? (St. John's wort, Goldenseal, Ginseng, Milk thistle).

Special Client Considerations and High-Risk Populations

• Older Adults:

  • Anticholinergic Susceptibility: Marked vulnerability to central and peripheral anticholinergic toxicity (diphenhydramine, tiotropium), precipitating acute urinary retention, acute glaucoma crises, severe constipation, falls, cognitive delirium, and confusion.

  • Cardiovascular Hemodynamics: Heightened risk of first-dose syncope, severe orthostatic hypotension, and falls when initiating thiazides, loop diuretics, and alpha-1 blockers (prazosin); start with low doses and titrate slowly.

  • Digoxin Toxicity: Age-related reductions in glomerular filtration rate (GFR) and lean muscle mass elevate serum digoxin levels; cognitive confusion and delirium are often the sole presenting signs of digoxin toxicity in older clients.

• Adolescents:

  • High-risk recreational misuse and "pharming" challenges involving OTC cough and cold products (dextromethorphan dissociation and diphenhydramine delirium/arrhythmias).

• African-American Clients:

  • Clinical trials establish that monotherapy with calcium channel blockers (diltiazem) and thiazide diuretics (HCTZ) produces the most significant, effective blood pressure reduction and anginal control compared to beta blockers or ACE inhibitors.

• Pregnancy and Lactation (Black-Box Teratogenicity):

  • Strictly Contraindicated in Pregnancy: Lisinopril (ACEI), Valsartan (ARB), Warfarin (vitamin K antagonist), Atorvastatin (statin), and Atenolol (beta blocker).

  • Lactation Prohibitions: Diphenhydramine is strictly contraindicated during breastfeeding (excreted in breast milk, causing neonatal somnolence and respiratory sensitivity); tiotropium and atenolol must be avoided.

  • Emergency Thrombolytic Use: Alteplase requires emergency multi-specialist risk-benefit evaluation during pregnancy due to catastrophic placental abruption risks.

• Renal Impairment:

  • Thiazide diuretics (HCTZ) become ineffective in significant renal failure ($CrCl < 30\,\text{mL/min}$); loop diuretics (furosemide) retain clinical efficacy even at low GFR levels.

  • Atenolol is excreted unchanged by the kidneys and requires dose reduction in renal failure.

  • Potassium-sparing diuretics (spironolactone), ACE inhibitors (lisinopril), and ARBs (valsartan) carry high risks of severe hyperkalemia and acute azotemia; close monitoring of BUN, creatinine, and potassium is required.

• Diabetes Mellitus:

  • Thiazide (HCTZ) and loop (furosemide) diuretics induce glycogenolysis and impair insulin release, elevating blood glucose.

  • Albuterol stimulates hepatic glycogenolysis, causing transient hyperglycemia.

  • Beta blockers (atenolol, metoprolol) mask the autonomic warning signs of hypoglycemia (tachycardia, tremors, palpitations); diaphoresis (sweating) remains intact.

• Gout and Systemic Lupus Erythematosus (SLE):

  • Thiazide and loop diuretics competitively block uric acid secretion in the renal tubules, elevating serum uric acid and triggering acute gout flares.

  • HCTZ triggers severe photosensitivity reactions, which can incite systemic flares in clients with SLE.

• Asthma and COPD:

  • Beta blockers must be used with extreme caution due to bronchospasm risks; non-selective beta blockers are contraindicated; cardioselective agents (atenolol, metoprolol) lose selectivity at elevated doses.

  • Anticholinergics (tiotropium) and antihistamines (diphenhydramine) cause drying of respiratory secretions, which can worsen mucus plugging.

• Heart Failure Nuances:

  • Metoprolol succinate, lisinopril, and valsartan improve long-term hemodynamics and reduce cardiac remodeling.

  • Cilostazol is BLACK-BOX CONTRAINDICATED in heart failure of any severity due to increased ventricular dysrhythmia and mortality risks.

• Tobacco Smokers:

  • Nicotine induces peripheral arterial vasospasm, blunting the direct vasodilatory actions of cilostazol; smoking cessation is essential.

Universal Antihypertensive Protocols and Hypertension Reference

• Universal Core Instructions for ALL Antihypertensive Medications:

  • Instruction 1: Self-monitor blood pressure at least once weekly and maintain an accurate, dated written log for clinic visits.

  • Instruction 2: Commit to a comprehensive lifestyle plan: adhere to the DASH diet with strict dietary sodium restriction ($< 2\,\text{g/day}$), maintain moderate daily physical exercise, achieve weight reduction, and eliminate alcohol and tobacco.

  • Instruction 3: Continue taking the prescribed medication daily, even when feeling entirely well; hypertension is an asymptomatic condition.

  • Instruction 4: Never abruptly stop taking antihypertensive medications; sudden discontinuation precipitates severe rebound hypertension, acute anginal attacks, or fatal myocardial infarction.

• AHA/ACC Blood Pressure Categorization Schema:

  • Normal Blood Pressure: Systolic $< 120\,\text{mmHg}$ and diastolic $< 80\,\text{mmHg}$.

  • Elevated Blood Pressure: Systolic $120\text{ to }129\,\text{mmHg}$ and diastolic $< 80\,\text{mmHg}$.

  • Stage 1 Hypertension: Systolic $130\text{ to }139\,\text{mmHg}$ or diastolic $80\text{ to }89\,\text{mmHg}$.

  • Stage 2 Hypertension: Systolic $\ge 140\,\text{mmHg}$ or diastolic $\ge 90\,\text{mmHg}$.

  • Clinical Management Goals: Target $< 140/90\,\text{mmHg}$ for individuals aged $< 60\,\text{years}$; target $< 150/90\,\text{mmHg}$ for individuals aged $\ge 60\,\text{years}$.

• Congestive Heart Failure Hemodynamic Profiles:

  • Right-Sided Heart Failure (Systemic Venous Congestion): Manifests with bilateral dependent peripheral edema, hepatomegaly, splenomegaly, ascites, and jugular venous distention (JVD).

  • Left-Sided Heart Failure (Pulmonary Congestion): Manifests with pulmonary crackles, wheezing, orthopnea, paroxysmal nocturnal dyspnea (PND), tachypnea, and cough with frothy sputum.

  • Non-Pharmacologic Management: Sodium-restricted diet ($< 2\,\text{g/day}$), fluid restriction, abstinence from alcohol, tobacco cessation, and daily weight monitoring.

• Angina Pectoris Mechanisms & Classes:

  • Inadequate oxygen delivery to the myocardium relative to myocardial oxygen demand, caused by fixed atherosclerotic plaque or dynamic coronary vasospasm.

  • Managed by three core antianginal classes: Organic Nitrates (nitroglycerin), Beta Blockers (atenolol, metoprolol), and Calcium Channel Blockers (diltiazem).

Medication Calculations and Administration Mathematics

• General Calculation Formulas:

  • Solid Tablets & Oral Liquids Formula:         $\text{Dose to Administer} = \left(\frac{\text{Desired Dose [D]}}{\text{Dose on Hand [H]}}\right) \times \text{Quantity / Vehicle [Q]}$

  • Pounds to Kilograms Weight Conversion:         $\text{Weight (kg)} = \frac{\text{Weight (lb)}}{2.2}$

  • Weight-Based Pediatric and Adult Dosing:         $\text{Total Required Dose} = \text{Prescribed Dose per kg} \times \text{Client Weight in kg}$

  • Electronic IV Infusion Pump Flow Rate:         $\text{Flow Rate (mL/hr)} = \frac{\text{Total Prescribed Volume (mL)}}{\text{Total Infusion Time (hr)}}$

  • Manual Gravity Drop Rate Formula:         $\text{Drop Rate (gtt/min)} = \frac{\text{Total Volume to Infuse (mL)} \times \text{Tubing Drop Factor (gtt/mL)}}{\text{Infusion Time in Minutes (min)}}$

  • Heparin Infusion Calculations:         $\text{Solution Concentration (units/mL)} = \frac{\text{Total Active Heparin Units}}{\text{Total Solution Volume in Bag (mL)}}$         $\text{Pump Flow Rate (mL/hr)} = \frac{\text{Prescribed Rate (units/hr)}}{\text{Solution Concentration (units/mL)}}$

• Worked Clinical Practice Problems:

  • Problem 1 (Oral/Parenteral Solution): Furosemide $40\,\text{mg}$ IV push is ordered for acute pulmonary congestion. The medication vial is labeled $10\,\text{mg/mL}$. Calculate the volume to administer.         $\text{Volume} = \left(\frac{40\,\text{mg}}{10\,\text{mg}}\right) \times 1\,\text{mL} = 4\,\text{mL}$

  • Problem 2 (Heparin Infusion Rate): A regular heparin infusion bag contains $25{,}000\,\text{units}$ of Heparin Sodium in $250\,\text{mL}$ of $5\%$ Dextrose in Water ($D_5W$). The provider orders a continuous infusion of $1{,}000\,\text{units/hr}$. Calculate the IV infusion pump flow rate in $\text{mL/hr}$.         $\text{Concentration} = \frac{25{,}000\,\text{units}}{250\,\text{mL}} = 100\,\text{units/mL}$         $\text{Flow Rate} = \frac{1{,}000\,\text{units/hr}}{100\,\text{units/mL}} = 10\,\text{mL/hr}$

  • Problem 3 (Weight-Based Dosing): Enoxaparin $1\,\text{mg/kg}$ SQ every $12\,\text{hours}$ is ordered for an acute DVT. The client weighs $176\,\text{lb}$. Calculate the single dose in milligrams.         $\text{Weight (kg)} = \frac{176\,\text{lb}}{2.2} = 80\,\text{kg}$         $\text{Dose} = 1\,\text{mg/kg} \times 80\,\text{kg} = 80\,\text{mg}$

  • Problem 4 (Tablet Fractional Formulation): Warfarin Sodium $5\,\text{mg}$ PO is ordered at 1800. The medication drawer supplies scored tablets containing $2.5\,\text{mg}$. Calculate the number of tablets to dispense.         $\text{Tablets} = \frac{5\,\text{mg}}{2.5\,\text{mg}} = 2\,\text{tablets}$

  • Problem 5 (Gravity Flow Drip Rate): Infuse $500\,\text{mL}$ of $0.9\%$ Normal Saline IV over a duration of $4\,\text{hours}$. The intravenous administration tubing has a drop factor of $15\,\text{gtt/mL}$. Calculate the manual gravity drip rate in $\text{gtt/min}$.         $\text{Time in Minutes} = 4\,\text{hours} \times 60\,\text{min/hr} = 240\,\text{minutes}$         $\text{Drop Rate} = \frac{500\,\text{mL} \times 15\,\text{gtt/mL}}{240\,\text{minutes}} = \frac{7{,}500}{240} = 31.25 \approx 31\,\text{gtt/min}$

  • Problem 6 (Weight-Based Heparin Titration): A heparin infusion protocol specifies administering $18\,\text{units/kg/hr}$. The client weighs $70\,\text{kg}$. The premixed heparin infusion bag concentration is $100\,\text{units/mL}$. Calculate the pump infusion rate in $\text{mL/hr}$.         $\text{Dose per Hour} = 18\,\text{units/kg/hr} \times 70\,\text{kg} = 1{,}260\,\text{units/hr}$         $\text{Flow Rate} = \frac{1{,}260\,\text{units/hr}}{100\,\text{units/mL}} = 12.6\,\text{mL/hr}$

  • Problem 7 (Parenteral Liquid Formulation): Diphenhydramine $25\,\text{mg}$ deep IM is prescribed for an allergic reaction. The available ampule contains $50\,\text{mg/mL}$. Calculate the volume to administer.         $\text{Volume} = \left(\frac{25\,\text{mg}}{50\,\text{mg}}\right) \times 1\,\text{mL} = 0.5\,\text{mL}$

  • Problem 8 (Cardiac Glycoside Tablet Calculation): Digoxin $0.125\,\text{mg}$ PO daily is ordered for a client with atrial fibrillation. Available tablets contain $0.25\,\text{mg}$. Calculate the number of tablets to dispense.         $\text{Tablets} = \frac{0.125\,\text{mg}}{0.25\,\text{mg}} = 0.5\text{ (or } \frac{1}{2}\text{) tablet}$         Critical Nursing Action: Auscultate apical pulse for $1\text{ full minute}$ prior to administration; hold if $HR < 60\,\text{beats/min}$.